News

Video

Countdown to CIME 2024: More CME, more innovation, more interaction

Program cochair Arjan Hura, MD, previews this year’s extended schedule with discussions on retina gene therapies, corneal endothelial diseases, and oculoplastics, along with hands-on experiences.

With an expanded program providing attendees with more CME credit and hands-on experience, the 18th Annual Controversies in Modern Eye Care (CIME) meeting will take place at the Hilton Los Angeles/Universal City in California on May 4, 2024.

Arjan Hura, MD, Robert Maloney, MD, and Neda Shamie, MD, from the Maloney-Shamie Vision Institute in Los Angeles are the program cochairs of the meeting. Hura recently spoke with Ophthalmology Times® and Optometry Times® about the conference schedule, which will cover the latest innovations and discussions in cataract and refractive surgery, retina gene therapies, corneal endothelial diseases, and oculoplastics, providing attendees with more CME credits and interactive experiences with industry partners.

To learn more about or to register for the 18th Annual CIME meeting, click here.

Video Transcript

Editor’s note - The following transcript has been lightly edited for clarity.

Arjan Hura, MD:

My name is Arjan Hura, MD. I’m a refractive, cataract, and anterior segment surgeon at the Maloney-Shamie Vision Institute in Los Angeles, California. We are so excited to welcome you back this year to the next iteration of our Controversies in Modern Eye Care symposium taking place on Saturday, May 4, 2024, in Los Angeles.

The history of the meeting has been such that this is a venue where we always discuss what’s new, what’s up and coming in modern eye care, but also, we don’t shy away from the controversies. We embrace different opinions in a healthy and respectful and positive manner.

There’s a lot of new and exciting technology coming on the horizon, not just on the cataract and refractive side of things but there’s a lot of interesting gene therapeutics taking place in retina. There’s some cell therapy being developed for corneal endothelial dystrophies. In the world of oculoplastics and thyroid eye disease, there’s a lot of exciting innovation taking place there as well.

For the first time ever, we’re having this event on a Saturday. We’re expanding the format. So it’s going to be a longer meeting, which means more CME than usual. The industry partners that are coming to this meeting are going to be bringing hands-on, live demo experiences.

Apart from just the benefits of networking, seeing your friends in person, I think there’s going to be a lot of exciting content [and] a lot of hands-on opportunities. We hope that this will be one of the most fulfilling and fun educational events of the year for you.

We can’t wait to see you Saturday, May 4. See you there!

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.